antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-5-6-19-24antibiotics-925Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИExperimental ResearchАнтибиотикочувствительность Neisseria meningitidis, выделенных от больных генерализованными формами менингококковой инфекции и от здоровых носителейAntibiotic Sensitivity of Neisseria meningitidis Isolated From Patients with Generalized Forms of Meningococcal Infection and From Healthy Carriershttps://orcid.org/0000-0001-6093-7493МАРТЕНСЭ. А.MARTENSE. A.

Мартенс Эльвира Акрамовна — заведующий клинико-диагностической лабораторией, младший научный сотрудник, ФГБУ «Детский научно-клинический центр инфекционных болезней ФМБА России»; ассистент кафедры медицинской микробиологии ФГБОУ ВО СЗГМУ им. И. И. Мечникова Минздрава России.WOS Researcher ID: CAG-4447-2022Scopus Author ID: 57206470215

Санкт-Петербург

Elvira A. Martens — Head of the Clinical Diagnostic Laboratory, Junior Researcher, Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; Assistant at the Department of Medical Microbiology North-Western State Medical University named after I. I. Mechnikov. WOS Researcher ID: CAG4447-2022Scopus Author ID: 57206470215 

Saint-Petersburg

https://orcid.org/0000-0001-8071-3243ЖЕЛЕЗОВАЛ. И.ZHELEZOVAL. I.

Железова Людмила Ильинична — к. м. н., старший научный сотрудник отдела медицинской микробиологии и молекулярной эпидемиологии. WOS Researcher ID: G-9662-2012Scopus Author ID: 6505716185

Санкт-Петербург

Lyudmila I. Zhelezova — Ph. D. in medicine. WOS Researcher ID: G-9662-2012Scopus Author ID: 6505716185

Saint-Petersburg

https://orcid.org/0000-0002-3480-8089ГОСТЕВВ. В.GOSTEVV. V.

Гостев Владимир Валерьевич — к. б. н., старший научный сотрудник — отдела медицинской микробиологии и молекулярной эпидемиологии ФГБУ «Детский научно-клинический центр инфекционных болезней ФМБА России»; доцент кафедры медицинской микробиологии ФГБОУ ВО СЗГМУ им. И. И. Мечникова Минздрава. WOS Researcher ID: P-1949-2016WOS Researcher ID: 55614534400

197022, г. Санкт-Петербург, ул Профессора Попова, д. 9

Vladimir V. Gostev — Ph. D. in biology, Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency, North-Western State Medical University named after I. I. Mechnikov. WOS Researcher ID: P-1949-2016WOS Researcher ID: 55614534400

197022, St. Petersburg, Professora Popova st., 9

guestvv11@gmail.comЛИХОЛЕТОВАД. В.LIKHOLETOVAD. V.

Лихолетова Дарья Вадимовна — лаборант-исследователь отдела медицинской микробиологии и молекулярной эпидемиологии.

Санкт-Петербург

Daria V. Likholetova — Laboratory researcher at the Department of Medical Microbiology and Molecular Epidemiology.

Saint-Petersburg

ГЛАДИНД. П.GLADIND. P.

Гладин Дмитрий Павлович — к. м. н., доцент, и. о. заведующего кафедрой микробиологии, вирусологии и иммунологии. Scopus Author ID: 6603374770

Санкт-Петербург

Dmitry P. Gladin — Ph. D. in medicine. Scopus Author ID: 6603374770

Saint-Petersburg

ФГБУ, «Детский научно-клинический центр по инфекционным болезням Федерального медико-биологического агентства»; ФГБОУ ВО «Северо-западный государственный медицинский университет им. И. И. Мечникова»РоссияPediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; North-Western State Medical University named after I. I. MechnikovRussian FederationФГБУ, «Детский научно-клинический центр по инфекционным болезням Федерального медико-биологического агентства»РоссияPediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological AgencyRussian FederationФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет»РоссияSaint-Petersburg State Pediatric Medical UniversityRussian Federation202208092022675-61924Copyright © МАРТЕНС Э.А., ЖЕЛЕЗОВА Л.И., ГОСТЕВ В.В., ЛИХОЛЕТОВА Д.В., ГЛАДИН Д.П., 20222022МАРТЕНС Э.А., ЖЕЛЕЗОВА Л.И., ГОСТЕВ В.В., ЛИХОЛЕТОВА Д.В., ГЛАДИН Д.П.MARTENS E.A., ZHELEZOVA L.I., GOSTEV V.V., LIKHOLETOVA D.V., GLADIN D.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/925

В исследование включено 50 изолятов Neisseria meningitidis, выделенных от больных генерализованными формами менингококковой инфекции, и 48 изолятов, выделенных от носителей. Идентификацию выделенных изолятов проводили методом MALDI-TOF масс-спектрометрии с использованием масс-спектрометра Microflex LT (Bruker Daltonics, Германия). Минимальные подавляющие концентрации (МПК) бензилпенициллина, ампициллина, цефтриаксона, меропенема, ципрофлоксацина, азитромицина, рифампицина, хлорамфеникола оценивались методом серийных разведений в агаре с интерпретацией результатов, согласно критериям EUCAST 2021. Клиническая устойчивость к пенициллину выявлена у 7% изолятов. Однако у всех изолятов с МПК>0,064 мкг/мл (n=26) обнаружены мутации в гене penA. Снижение чувствительности к рифампицину обнаружено у четырёх изолятов, выделенных от больных и у четырёх — выделенных у носителей. У семи из восьми изолятов со сниженной чувствительностью к рифампицину обнаружены мутации в гене rpoB. Устойчивость к цефтриаксону, меропенему, ципрофлоксацину не выявлена. 

The study included 50 isolates of Neisseria meningitidis isolated from patients with generalized forms of meningococcal infection and 48 isolates, which were isolated from carriers. The isolates were identified by MALDI-TOF mass spectrometry using a Microflex LT mass spectrometer (Bruker Daltonics, Germany). Minimum inhibitory concentrations (MICs) of benzylpenicillin, ampicillin, ceftriaxone, meropenem, ciprofloxacin, azithromycin, rifampicin, and chloramphenicol were assessed by the method of serial agar dilution with interpretation of the results according to EUCAST 2021 criteria. Clinical resistance to penicillin was detected in 7% of isolates. However, all isolates with MIC >0.064 µg/ml (n=26) had mutations in the penA gene. Decreased sensitivity to rifampicin was found in four isolates isolated from patients and four isolated from carriers. Seven out of eight isolates with reduced sensitivity to rifampicin had mutations in the rpoB gene. Resistance to ceftriaxone, meropenem, ciprofloxacin was not detected. 

Neisseria meningitidisменингококковая инфекцияантибиотикочувствительностьNeisseria meningitidismeningococcal infectionantibiotic sensitivityReferencesCollaborators GBDM. Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018; 17: 1061–1082. doi:10.1016/S1474-4422(18)30387-9.Collaborators GBDM. Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018; 17: 1061–1082. doi:10.1016/S1474-4422(18)30387-9.Edmond K., Clark A., Korczak V.S., Sanderson C., Griffiths U.K., Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. The Lancet Infectious diseases. 2010; 10: 317–328. doi:10.1016/S1473-3099(10)70048-7.Edmond K., Clark A., Korczak V.S., Sanderson C., Griffiths U.K., Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. The Lancet Infectious diseases. 2010; 10: 317–328. doi:10.1016/S1473-3099(10)70048-7.McNamara L.A., MacNeil J.R., Cohn A.C., Stephens D.S. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. The Lancet Infectious diseases. 2018; 18: e272–e81. doi:10.1016/S1473-3099(18)30124-5.McNamara L.A., MacNeil J.R., Cohn A.C., Stephens D.S. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. The Lancet Infectious diseases. 2018; 18: e272–e81. doi:10.1016/S1473-3099(18)30124-5.Nadel S. Treatment of Meningococcal Disease. J Adolescent Health. 2016; 59: S21–8. doi:10.1016/j.jadohealth.2016.04.013.Nadel S. Treatment of Meningococcal Disease. J Adolescent Health. 2016; 59: S21–8. doi:10.1016/j.jadohealth.2016.04.013.Girgis N., Sultan Y., Frenck R.W., Jr., El-Gendy A., Farid Z., Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J. 1998; 17: 816–819. doi:00006454-199809000-00013.Girgis N., Sultan Y., Frenck R.W., Jr., El-Gendy A., Farid Z., Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J. 1998; 17: 816–819. doi:00006454-199809000-00013.Sidorenko S., Zakharenko S., Lobzin Y., Zhdanov K., Martens E., Gostev V. et al. Observational study of nasopharyngeal carriage of Neisseria meningitis in applicants to a military academy in the Russian Federation. Intern J Infect Dis. 2019; 81: 12–16. doi:10.1016/j.ijid.2018.12.012.Sidorenko S., Zakharenko S., Lobzin Y., Zhdanov K., Martens E., Gostev V. et al. Observational study of nasopharyngeal carriage of Neisseria meningitis in applicants to a military academy in the Russian Federation. Intern J Infect Dis. 2019; 81: 12–16. doi:10.1016/j.ijid.2018.12.012.The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http://www.eucast.org.The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http://www.eucast.org.Hong E., Deghmane A.E., Taha M.K. Acquisition of Beta-Lactamase by Neisseria meningitidis through Possible Horizontal Gene Transfer. Antimicrob Agents Chemother. 2018; 62 (9): e00831–18. doi:10.1128/AAC.00831-18.Hong E., Deghmane A.E., Taha M.K. Acquisition of Beta-Lactamase by Neisseria meningitidis through Possible Horizontal Gene Transfer. Antimicrob Agents Chemother. 2018; 62 (9): e00831–18. doi:10.1128/AAC.00831-18.Taha M-K., Vázquez J.A., Hong E., Bennett D.E., Bertrand S., Bukovski S. et al. Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrobial Agents Chemother. 2007; 51: 2784–2792. doi:10.1128/AAC.00412-07.Taha M-K., Vázquez J.A., Hong E., Bennett D.E., Bertrand S., Bukovski S. et al. Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrobial Agents Chemother. 2007; 51: 2784–2792. doi:10.1128/AAC.00412-07.Zapun A., Morlot C., Taha M.K. Resistance to beta-Lactams in Neisseria ssp. Due to Chromosomally Encoded Penicillin-Binding Proteins. Antibiotics (Basel). 2016; 5 (4): 35. doI:10.3390/antibiotics5040035.Zapun A., Morlot C., Taha M.K. Resistance to beta-Lactams in Neisseria ssp. Due to Chromosomally Encoded Penicillin-Binding Proteins. Antibiotics (Basel). 2016; 5 (4): 35. doI:10.3390/antibiotics5040035.Deghmane A.E., Hong E., Taha M.K. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. J Antimicrob Chemother. 2017; .72 (1): 95–98. doI:10.1093/jac/dkw400.Deghmane A.E., Hong E., Taha M.K. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. J Antimicrob Chemother. 2017; .72 (1): 95–98. doI:10.1093/jac/dkw400.Młynarczyk-Bonikowska B., Majewska A., Malejczyk M., Młynarczyk G., Majewski S. Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century. Med Microbiol Immunol. 2020; 209 (2): 95-108. doi:10.1007/s00430-019-00651-4.Młynarczyk-Bonikowska B., Majewska A., Malejczyk M., Młynarczyk G., Majewski S. Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century. Med Microbiol Immunol. 2020; 209 (2): 95-108. doi:10.1007/s00430-019-00651-4.Galimand M., Gerbaud G., Guibourdenche M., Riou J.Y., Courvalin P. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med. 1998; 339: 868–874. doi:10.1056/NEJM199809243391302.Galimand M., Gerbaud G., Guibourdenche M., Riou J.Y., Courvalin P. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med. 1998; 339: 868–874. doi:10.1056/NEJM199809243391302.Eliakim-Raz N., Lador A., Leibovici-Weissman Y., Elbaz M., Paul M., Leibovici L. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015; 70: 979–996. doi:10.1093/jac/dku530.Eliakim-Raz N., Lador A., Leibovici-Weissman Y., Elbaz M., Paul M., Leibovici L. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015; 70: 979–996. doi:10.1093/jac/dku530.Singhal S., Purnapatre K.P., Kalia V., Dube S., Nair D., Deb M. et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis. 2007; 13: 1614–1616. doi:10.3201/eid1310.060820.Singhal S., Purnapatre K.P., Kalia V., Dube S., Nair D., Deb M. et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis. 2007; 13: 1614–1616. doi:10.3201/eid1310.060820.Skoczynska A., Alonso J.M., Taha M.K. Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg Infect Dis. 2008; 14: 1322–1323. doi:10.3201/eid1408.080040.Skoczynska A., Alonso J.M., Taha M.K. Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg Infect Dis. 2008; 14: 1322–1323. doi:10.3201/eid1408.080040.Wu H.M., Harcourt B.H., Hatcher C.P., Wei S.C., Novak R.T., Wang X. et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009; 360: 886–892. doi:10.1056/NEJMoa0806414.Wu H.M., Harcourt B.H., Hatcher C.P., Wei S.C., Novak R.T., Wang X. et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009; 360: 886–892. doi:10.1056/NEJMoa0806414.Tzanakaki G., Georgakopoulou T., Xirogianni A., Papandreou A., Deghmane A-E., Magaziotou I. et al. First report of meningococcal ciprofloxacin resistance in Greece due to invasive isolates of the sequence type ST-3129. Eur J Clin Microbiol Infect Dis. 2020; 39: 2467–2470. doi:10.1007/s10096-020-03965-x.Tzanakaki G., Georgakopoulou T., Xirogianni A., Papandreou A., Deghmane A-E., Magaziotou I. et al. First report of meningococcal ciprofloxacin resistance in Greece due to invasive isolates of the sequence type ST-3129. Eur J Clin Microbiol Infect Dis. 2020; 39: 2467–2470. doi:10.1007/s10096-020-03965-x.Willerton L., Lucidarme J., Campbell H., Caugant D.A., Claus H., Jacobsson S. et al. Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. J Infect. 2020; 81: 575–584. doi:10.1016/j.jinf.2020.08.030.Willerton L., Lucidarme J., Campbell H., Caugant D.A., Claus H., Jacobsson S. et al. Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. J Infect. 2020; 81: 575–584. doi:10.1016/j.jinf.2020.08.030.Potts C.C., Retchless A.C., McNamara L.A., Marasini D., Reese N., Swint S. et al. Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of beta-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States. Clin Infect Dis. 2021; 73: 1185–1193. doi:10.1093/cid/ciab358.Potts C.C., Retchless A.C., McNamara L.A., Marasini D., Reese N., Swint S. et al. Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of beta-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States. Clin Infect Dis. 2021; 73: 1185–1193. doi:10.1093/cid/ciab358.Taormina G., Campos J., Sweitzer J., Retchless A.C., Lunquest K., McNamara L.A. et al. Beta-lactamase-producing, ciprofloxacin-resistant Neisseria meningitidis isolated from a 5-month-old boy in the United States. J Pediatric Infect Dis Soc. 2021; 10: 379–381. dpi:10.1093/jpids/piaa085.Taormina G., Campos J., Sweitzer J., Retchless A.C., Lunquest K., McNamara L.A. et al. Beta-lactamase-producing, ciprofloxacin-resistant Neisseria meningitidis isolated from a 5-month-old boy in the United States. J Pediatric Infect Dis Soc. 2021; 10: 379–381. dpi:10.1093/jpids/piaa085.

The authors declare that there are no conflicts of interest present.